title: Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at the 50th ASCO Annual Meeting.
abstract: The 6th Annual Meeting of the United States Chinese Anti-Cancer Association (USCACA) was held in conjunction with the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) on May 30, 2014 in Chicago, Illinois, the United States of America. With a focus on personalized medicine, the conference featured novel approaches to investigate genomic aberrations in cancer cells and innovative clinical trial designs to expedite cancer drug development in biomarker-defined patient populations. A panel discussion further provided in-depth advice on advancing development of personalized cancer medicines in China. The conference also summarized USCACA key initiatives and accomplishments, including two awards designated to recognize young investigators from China for their achievements and to support their training in the United States. As an effort to promote international collaboration, USCACA will team up with Chinese Society of Clinical Oncology (CSCO) to host a joint session on "Breakthrough Cancer Medicines" at the upcoming CSCO Annual Meeting on September 20th, 2014 in Xiamen, China.
authors.affiliation: Executive Committee of the US Chinese Anti-Cancer Association (USCACA), Martinez, CA 94553, USA; Department of Pediatrics, University of Illinois at Chicago, Chicago, IL 60612, USA. weizhang.chicago@gmail.com.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Shi-Yuan
authors.initials: SY
authors.lastname: Cheng
authors.forename: Li-Fang
authors.initials: LF
authors.lastname: Hou
authors.forename: Li
authors.initials: L
authors.lastname: Yan
authors.forename: Yun-Guang
authors.initials: YG
authors.lastname: Tong
mesh_terms: D000970:Antineoplastic Agents; D001363:Awards and Prizes; D002641:Chicago; D002681:China; D055808:Drug Discovery; D023281:Genomics; D006801:Humans; D008495:Medical Oncology; D009369:Neoplasms; D057285:Precision Medicine; D012955:Societies, Medical; D014481:United States
chemical_list: D000970:Antineoplastic Agents
references.citation: Chin J Cancer. 2013 Jul;32(7):357-62
references.pmid: 23823625
references.citation: J Clin Oncol. 2006 May 10;24(14):2137-50
references.pmid: 16682732
references.citation: Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21083-8
references.pmid: 24324171
references.citation: Chin J Cancer. 2012 Nov;31(11):505-6
references.pmid: 23121765
references.citation: Nature. 2014 May 1;509(7498):91-5
references.pmid: 24670651
references.citation: Science. 2012 Dec 21;338(6114):1622-6
references.pmid: 23258894
references.citation: Lancet Oncol. 2014 Apr;15(5):489-538
references.pmid: 24731404
references.citation: Nat Methods. 2013 Mar;10(3):190-1
references.pmid: 23570041
references.citation: Chin J Cancer. 2012 Jul;31(7):315-8
references.pmid: 22739264